Tectonic Therapeutic (TECX) EBITDA (2017 - 2026)

Tectonic Therapeutic (TECX) has 10 years of EBITDA data on file, last reported at -$27.3 million in Q1 2026.

• EBITDA for Q1 2026 came in at -$27.3 million, down 49.2% year-over-year; the trailing twelve-month figure through Mar 2026 was -$93.0 million (down 46.87% YoY), and the FY2025 annual result was -$84.0 million, down 44.85% from the prior year.
• EBITDA fell to -$27.3 million in Q1 2026 per TECX's latest filing, from -$21.5 million in the prior quarter.
• Over five years, EBITDA peaked at -$9.4 million in Q4 2023 and troughed at -$29.8 million in Q1 2022.
• A 5-year average of -$19.5 million and a median of -$21.5 million in 2025 frame the typical range for EBITDA.
• The sharpest annual moves came in 2023 and 2025: EBITDA soared 62.89% in 2023, then plunged 95.53% in 2025.
• A 5-year view of EBITDA shows it stood at -$25.3 million in 2022, then soared by 62.89% to -$9.4 million in 2023, then tumbled by 49.25% to -$14.0 million in 2024, then slumped by 53.78% to -$21.5 million in 2025, then retreated by 26.89% to -$27.3 million in 2026.
• Business Quant data shows TECX's EBITDA at -$27.3 million in Q1 2026, -$21.5 million in Q4 2025, and -$21.9 million in Q3 2025.